NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:NMR - US65535H2085 - ADR
8.45 USD
+0.06 (+0.72%)
8.42 USD
-0.03 (-0.36%)
We assign a fundamental rating of 3 out of 10 to NMR. NMR was compared to 235 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
In the past 5 years NMR has always been profitable.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of NMR (0.61%) is worse than 68.51% of its industry peers.
NMR has a Return On Equity of 10.62%. This is in the better half of the industry: NMR outperforms 60.85% of its industry peers.
NMR has a worse Return On Invested Capital (0.66%) than 68.51% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 7.13%.
The last Return On Invested Capital (0.66%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 10.62% | ||
| ROIC | 0.66% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
NMR has a Profit Margin of 8.05%. This is in the lower half of the industry: NMR underperforms 63.40% of its industry peers.
NMR's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 11.60%, NMR is doing worse than 64.26% of the companies in the same industry.
In the last couple of years the Operating Margin of NMR has declined.
Looking at the Gross Margin, with a value of 43.38%, NMR is in line with its industry, outperforming 45.96% of the companies in the same industry.
NMR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.6% | ||
| PM (TTM) | 8.05% | ||
| GM | 43.38% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
Compared to 1 year ago, NMR has less shares outstanding
NMR has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, NMR has an improved debt to assets ratio.
2.2 Solvency
NMR has an Altman-Z score of -0.20. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
NMR has a Altman-Z score of -0.20. This is in the lower half of the industry: NMR underperforms 75.74% of its industry peers.
A Debt/Equity ratio of 10.65 is on the high side and indicates that NMR has dependencies on debt financing.
With a Debt to Equity ratio value of 10.65, NMR is not doing good in the industry: 87.23% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.65 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.2 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.28. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Current ratio (0.28) than 81.70% of its industry peers.
NMR has a Quick Ratio of 0.28. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.28, NMR is not doing good in the industry: 81.70% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.52% over the past year.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
Looking at the last year, NMR shows a decrease in Revenue. The Revenue has decreased by -2.45% in the last year.
The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
3.2 Future
NMR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.00% yearly.
NMR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.88% yearly.
EPS Next Y10.39%
EPS Next 2Y2.52%
EPS Next 3Y3%
EPS Next 5YN/A
Revenue Next Year-18.17%
Revenue Next 2Y-9.64%
Revenue Next 3Y-5.88%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.30, the valuation of NMR can be described as reasonable.
NMR's Price/Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 70.21% of the companies in the same industry.
When comparing the Price/Earnings ratio of NMR to the average of the S&P500 Index (26.60), we can say NMR is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 10.73, the valuation of NMR can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 68.51% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, NMR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.3 | ||
| Fwd PE | 10.73 |
4.2 Price Multiples
70.21% of the companies in the same industry are more expensive than NMR, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.85 |
4.3 Compensation for Growth
NMR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.99
PEG (5Y)0.94
EPS Next 2Y2.52%
EPS Next 3Y3%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.91%, NMR has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 6.65, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.91% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
18.37% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP18.37%
EPS Next 2Y2.52%
EPS Next 3Y3%
8.45
+0.06 (+0.72%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners42.52%
Inst Owner Change1.65%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.79B
Revenue(TTM)4.60T
Net Income(TTM)370.05B
Analysts73.33
Price Target8.07 (-4.5%)
Short Float %0.07%
Short Ratio2.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.91% |
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP18.37%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.89%
PT rev (3m)4.37%
EPS NQ rev (1m)40.6%
EPS NQ rev (3m)43.2%
EPS NY rev (1m)3.61%
EPS NY rev (3m)11.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.3 | ||
| Fwd PE | 10.73 | ||
| P/S | 0.85 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.11 | ||
| P/tB | 1.11 | ||
| EV/EBITDA | 20.85 |
EPS(TTM)0.82
EY9.7%
EPS(NY)0.79
Fwd EY9.32%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS10
BVpS7.58
TBVpS7.58
PEG (NY)0.99
PEG (5Y)0.94
Graham Number11.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 10.62% | ||
| ROCE | 1.62% | ||
| ROIC | 0.66% | ||
| ROICexc | 0.74% | ||
| ROICexgc | 0.76% | ||
| OM | 11.6% | ||
| PM (TTM) | 8.05% | ||
| GM | 43.38% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-ScoreN/A
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.65 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 62.4 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z | -0.2 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
EPS Next Y10.39%
EPS Next 2Y2.52%
EPS Next 3Y3%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
Revenue Next Year-18.17%
Revenue Next 2Y-9.64%
Revenue Next 3Y-5.88%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year26897.8%
EBIT Next 3Y533.42%
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A
NOMURA HOLDINGS INC-SPON ADR / NMR FAQ
Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a fundamental rating of 3 / 10 to NMR.
What is the valuation status of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?
ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.
Can you provide the profitability details for NOMURA HOLDINGS INC-SPON ADR?
NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.
What is the financial health of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?
The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.
What is the earnings growth outlook for NOMURA HOLDINGS INC-SPON ADR?
The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 10.39% in the next year.